Enzalutamide is approved for the treatment of castration-sensitive non-metastatic prostate cancer in cases of biochemical recurrence. Studies have shown that enzalutamide significantly prolongs the overall survival of patients with this form of the disease. There was a statistically significant decrease in the risk of death compared to placebo. Enzalutamide also significantly reduces the risk of disease progression. A greater than 50 percent decrease in serum PSA was observed in patients treated with enzalutamide. Treatment with enzalutamide is associated with a significant improvement in radiographically confirmed progression-free survival. The recommended dose is 160 mg of enzalutamide per day. Enzalutamide is approved based on the results of clinical trials in many countries.